• A Mouse Model for Studying Pancreatic Tumor Resection and Adjuvant Therapy

A Mouse Model for Studying Pancreatic Tumor Resection and Adjuvant Therapy

Researchers have developed mice that develop focal, resectable pancreatic tumors closely resembling human pancreatic ductal adenocarcinomas (PDACs) that can be used to test adjuvant therapies, according to new research in the August issue of Gastroenterology. The authors show that administration of gemcitabine after resection of the tumors activates natural killer (NK) cell-mediated

Read more
  • Biomarker of Early-stage Aggressive Colon Cancer

Biomarker of Early-stage Aggressive Colon Cancer

Lack of the biomarker CDX2 identifies a subgroup of patients with high-risk stage II colon cancer who appeared to benefit from adjuvant chemotherapy. These patients are usually treated with surgery alone. The findings come from a study published online January 21 in the New England Journal of Medicine. Piero Dalerba

Read more
  • How Many Patients are Screened for HBV Infection Before Chemotherapy?

How Many Patients are Screened for HBV Infection Before Chemotherapy?

Only a small percentage of patients receiving chemotherapy are screened for hepatitis B virus (HBV) infection, although the proportion of patients screened has increased slightly over the past decade, researchers report in the May issue of Clinical Gastroenterology and Hepatology. Strategies are needed to ensure that patients receiving chemotherapy are

Read more
  • Does Cancer Treatment Bring Back HCV Infection?

Does Cancer Treatment Bring Back HCV Infection?

Treated hepatitis C virus (HCV) infections do not return after patients receive chemotherapy or immunosuppressive therapy, researchers report in the June issue of Clinical Gastroenterology and Hepatology. Cancer chemotherapy leads to HCV reactivation in patients with chronic infections, but little is known about the effect of chemotherapy on HCV infections

Read more

Sensitizing Colorectal Tumors to Chemotherapy

Although colorectal tumors with microsatellite instability (MSI) are usually considered to have a poor response to 5-fluorouracil–based chemotherapy, researchers have identified a subset that actually respond well to chemotherapy. These tumors express a dominant-negative form of the chaperone HSP110, according to the February issue of Gastroenterology. Colorectal cancer (CRC) is

Read more

Can We Increase the Sensitivity of Pancreatic Cancer Cells to Chemotherapeutics?

Researchers have identified small molecules that increase the ability of chemotherapeutic agents to kill pancreatic cancer cells and slow tumor growth in mice, according to the February issue of Gastroenterology. One way that chemotherapeutics such gemcitabine, 5-fluorouracil, and platinum-based compounds kill cancer cells is by causing tumor suppressor proteins to

Read more

Why Do Only Some Gastric Tumors Respond to Therapy?

Tumors from patients with gastric cancer can be divided into subgroups, based on their gene expression pattern. This information can be used to select the best treatment, according to Patrick Tan and colleagues in the August issue of Gastroenterology. Gastric tumors have large, inter-individual differences in aggressiveness, histopathology features, and

Read more

Surviving Childhood Cancer Increases GI Risks

Individuals who received therapy for cancer during childhood have an increased risk of developing GI complications later in life, according to Robert Goldsby et al. in the May issue of Gastroenterology. About 80% of children who receive cancer therapy survive more than 5 years; therapies can be especially toxic to

Read more